Cross-Sector entity
Geode Capital Management LLC is most often covered alongside Weiss Ratings, which appears in 5 of these 9 stories. The 56-day window averages about 1.1 stories each week. The busiest single day carried 2. Coverage clusters in markets, which accounts for 4 of those 9, with the remainder spread across 3 other categories.
9 verified stories tracked
Last mentioned: Aug 17, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Geode Capital Management LLC is most often covered alongside Weiss Ratings, which appears in 5 of these 9 stories. The 56-day window averages about 1.1 stories each week. The busiest single day carried 2. Coverage clusters in markets, which accounts for 4 of those 9, with the remainder spread across 3 other categories. The tracked stories average 2.6 original sources each. This profile follows 9 Cross-Sector stories mentioning Geode Capital Management LLC across the period from June 23, 2026 to August 17, 2026. 0% of these stories carry negative sentiment.
Computed from the 9 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Geode Capital Management LLC. Shared-story counts are live from our verified record — not editorial picks.
13F disclosures reported
Multiple outlets reported the SEC Form 13F filings, including that Zoetis shares opened at $73.64 on Friday.
Q2 2026 United Super reductions
United Super cut Nebius by 20.5%, selling 3,390 shares to hold 13,147, and reduced Zoetis by 95.6%, selling 251,749 shares to hold 11,600.
Q1 2026 Nebius position increases
Amundi lifted Nebius by 10.6% to 1,343,954 shares worth $139,449,000; Lombard Odier, HB Wealth Management, Wealth Alliance, Empirical Financial Services, and Aspen Grove Capital also added or initiated Nebius positions.
Q4 2025 institutional accumulation
Geode Capital Management boosted its Nebius stake by 1,095.7% to 2,046,799 shares worth $169,840,000, while Vanguard added 12.9% to its Zoetis position and J. Stern & Co. lifted Zoetis by 12,431.2%.
The State of Wyoming disclosed new Q2 2026 13F positions in Cardinal Health ($921K) and Builders FirstSource ($828K), but the larger signal is institutional accumulation: CAH is 87.17% institutionally owned with Vanguard and Norges adding, while BLDR is 95.53% owned despite a Q2 earnings miss.
Source: dailypolitical.com · tickerreport.com
United Super, in its capacity as trustee for the Construction & Building Unions Superannuation Fund, cut its Nebius stake by 20.5% to $3.63 million and nearly exited Zoetis, reducing that position by 95.6% to $834,000 in Q2 2026. The 13F reveals rotation away from animal health while retaining AI-infrastructure exposure.
Source: Ticker Report · Daily Political
Safe Pro Group reported a quarterly EPS of -$0.15, one cent below consensus, but shares soared 37.7% on 21x average volume. The move pushed market cap to $128.89M even as negative net margin widened to 800.91%.
Source: MarketBeat · themarketsdaily.com
Ensysce Biosciences short interest soared 619.9% to 364,278 shares as its stock trades at $0.30, while Focus Universal posted just $0.05M in quarterly revenue. The data highlights severe financial fragility across two small healthcare and device innovators.
SCYNEXIS shorts collapsed 87.6% to 320,181 shares, signaling bear exhaustion, while Ensysce Biosciences short interest exploded 619.9% to 364,278. Focus Universal also saw a 282.8% build, reflecting a stark divergence in microcap biotech sentiment.
Source: tickerreport.com · dailypolitical.com
A major Shuttle Pharmaceuticals shareholder just poured $110,694 into the beaten-down stock, buying 32,591 shares at near all-time lows. For healthcare investors, this insider vote of confidence in a radiation oncology developer could signal upcoming clinical catalysts or a potential turnaround.
A $110,694 insider purchase by Financial Lp Hrt in Shuttle Pharmaceuticals boosts the owner’s stake to 78,597 shares just as the micro-cap trades near $2.90 lows. For biotech investors, this accumulation could reflect confidential knowledge about the radiation sensitizer pipeline's progress.
Source: Markets Daily · Daily Political
A wave of institutional buying in NVIDIA highlights the stock’s allure, with Paragon Capital’s Q1 2026 filing revealing a 288.8% stake increase. The move underscores how deep the conviction runs among hedge funds and sovereign wealth funds.
Source: Zolmax · Markets Daily
Creek Drive Management Group initiates a $1.4 million position in EVLV, as institutional ownership reaches 66.65%. Large funds like Vanguard and State Street add to positions, and an analyst target of $10 highlights upside potential for the AI security firm.
Source: themarketsdaily.com · zolmax.com
